DiaMedica Therapeutics (DMAC) Competitors

$5.91 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$5.92 +0.01 (+0.25%)

As of 05/22/2026 04:04 PM Eastern

DMAC vs. AVBP, HROW, WVE, MPLT, and OLMA

Should you buy DiaMedica Therapeutics stock or one of its competitors? MarketBeat compares DiaMedica Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DiaMedica Therapeutics include ArriVent BioPharma (AVBP), Harrow (HROW), WAVE Life Sciences (WVE), Maplight Therapeutics (MPLT), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry.

How does DiaMedica Therapeutics compare to ArriVent BioPharma?

DiaMedica Therapeutics (NASDAQ:DMAC) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

DiaMedica Therapeutics currently has a consensus target price of $12.33, suggesting a potential upside of 108.69%. ArriVent BioPharma has a consensus target price of $43.13, suggesting a potential upside of 61.34%. Given DiaMedica Therapeutics' higher probable upside, equities research analysts plainly believe DiaMedica Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, DiaMedica Therapeutics had 1 more articles in the media than ArriVent BioPharma. MarketBeat recorded 2 mentions for DiaMedica Therapeutics and 1 mentions for ArriVent BioPharma. DiaMedica Therapeutics' average media sentiment score of 0.00 equaled ArriVent BioPharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ArriVent BioPharma's return on equity of -48.98% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
ArriVent BioPharma	N/A	-48.98%	-45.44%

DiaMedica Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market.

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

Summary

ArriVent BioPharma beats DiaMedica Therapeutics on 8 of the 13 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Harrow?

DiaMedica Therapeutics (NASDAQ:DMAC) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

DiaMedica Therapeutics has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, Harrow has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

In the previous week, Harrow had 10 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 12 mentions for Harrow and 2 mentions for DiaMedica Therapeutics. Harrow's average media sentiment score of 0.70 beat DiaMedica Therapeutics' score of 0.00 indicating that Harrow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harrow	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by company insiders. Comparatively, 12.8% of Harrow shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

DiaMedica Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
Harrow	-5.57%	19.59%	2.26%

DiaMedica Therapeutics presently has a consensus price target of $12.33, suggesting a potential upside of 108.69%. Harrow has a consensus price target of $69.43, suggesting a potential upside of 110.39%. Given Harrow's higher possible upside, analysts plainly believe Harrow is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Harrow has higher revenue and earnings than DiaMedica Therapeutics. Harrow is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
Harrow	$272.30M	4.52	-$5.14M	-$0.41	N/A

Summary

Harrow beats DiaMedica Therapeutics on 11 of the 15 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to WAVE Life Sciences?

DiaMedica Therapeutics (NASDAQ:DMAC) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

DiaMedica Therapeutics has higher earnings, but lower revenue than WAVE Life Sciences. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
WAVE Life Sciences	$42.73M	28.73	-$204.38M	-$1.06	N/A

DiaMedica Therapeutics has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.32, indicating that its stock price is 232% less volatile than the broader market.

DiaMedica Therapeutics presently has a consensus target price of $12.33, suggesting a potential upside of 108.69%. WAVE Life Sciences has a consensus target price of $27.25, suggesting a potential upside of 327.12%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe WAVE Life Sciences is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

In the previous week, WAVE Life Sciences had 10 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 12 mentions for WAVE Life Sciences and 2 mentions for DiaMedica Therapeutics. WAVE Life Sciences' average media sentiment score of 0.07 beat DiaMedica Therapeutics' score of 0.00 indicating that WAVE Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
WAVE Life Sciences	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

DiaMedica Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. WAVE Life Sciences' return on equity of -56.76% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

Summary

WAVE Life Sciences beats DiaMedica Therapeutics on 11 of the 15 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by company insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Maplight Therapeutics' return on equity of 0.00% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
DiaMedica Therapeutics	N/A	-77.15%	-69.23%

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A

Maplight Therapeutics presently has a consensus target price of $35.50, indicating a potential upside of 23.48%. DiaMedica Therapeutics has a consensus target price of $12.33, indicating a potential upside of 108.69%. Given DiaMedica Therapeutics' higher possible upside, analysts clearly believe DiaMedica Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Maplight Therapeutics had 6 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 8 mentions for Maplight Therapeutics and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.00 beat Maplight Therapeutics' score of -0.32 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DiaMedica Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Maplight Therapeutics beats DiaMedica Therapeutics on 7 of the 13 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Olema Pharmaceuticals?

DiaMedica Therapeutics (NASDAQ:DMAC) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

DiaMedica Therapeutics has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market.

Olema Pharmaceuticals' return on equity of -46.00% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

DiaMedica Therapeutics presently has a consensus target price of $12.33, indicating a potential upside of 108.69%. Olema Pharmaceuticals has a consensus target price of $44.10, indicating a potential upside of 222.37%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Olema Pharmaceuticals had 6 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 8 mentions for Olema Pharmaceuticals and 2 mentions for DiaMedica Therapeutics. Olema Pharmaceuticals' average media sentiment score of 0.19 beat DiaMedica Therapeutics' score of 0.00 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Olema Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Olema Pharmaceuticals beats DiaMedica Therapeutics on 11 of the 13 factors compared between the two stocks.

Get DiaMedica Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMAC vs. The Competition

Export

Metric	DiaMedica Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$318.45M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-8.32	18.74	21.22	25.65
Price / Sales	N/A	323.98	553.92	86.28
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	6.72	7.09	10.37	7.14
Net Income	-$32.77M	$24.45M	$3.57B	$335.98M
7 Day Performance	6.10%	6.38%	6.40%	4.15%
1 Month Performance	-6.64%	2.43%	3.52%	2.54%
1 Year Performance	45.57%	62.98%	34.02%	35.05%

DiaMedica Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMAC DiaMedica Therapeutics	1.1757 of 5 stars	$5.91 flat	$12.33 +108.7%	+45.6%	$318.45M	N/A	N/A	20	Gap Down
AVBP ArriVent BioPharma	2.3725 of 5 stars	$26.73 -1.0%	$43.13 +61.3%	+31.0%	$1.24B	N/A	N/A	40	Analyst Forecast
HROW Harrow	4.5207 of 5 stars	$33.00 +0.1%	$69.43 +110.4%	+27.4%	$1.23B	$272.30M	N/A	180
WVE WAVE Life Sciences	3.1437 of 5 stars	$6.38 -0.6%	$27.25 +327.1%	+7.2%	$1.23B	$42.73M	N/A	240
MPLT Maplight Therapeutics	2.8858 of 5 stars	$28.75 -1.8%	$35.50 +23.5%	N/A	$1.23B	N/A	N/A	109	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMAC) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DiaMedica Therapeutics (DMAC) Competitors

DMAC vs. AVBP, HROW, WVE, MPLT, and OLMA

How does DiaMedica Therapeutics compare to ArriVent BioPharma?

Summary

How does DiaMedica Therapeutics compare to Harrow?

Summary

How does DiaMedica Therapeutics compare to WAVE Life Sciences?

Summary

How does DiaMedica Therapeutics compare to Maplight Therapeutics?

Summary

How does DiaMedica Therapeutics compare to Olema Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC vs. The Competition

DiaMedica Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DiaMedica Therapeutics (DMAC) Competitors

DMAC vs. AVBP, HROW, WVE, MPLT, and OLMA

How does DiaMedica Therapeutics compare to ArriVent BioPharma?

Do analysts prefer DMAC or AVBP?

Do insiders & institutionals hold more shares of DMAC or AVBP?

Does the media favor DMAC or AVBP?

Is DMAC or AVBP more profitable?

Which has more volatility and risk, DMAC or AVBP?

Which has better earnings and valuation, DMAC or AVBP?

Summary

How does DiaMedica Therapeutics compare to Harrow?

Which has more risk & volatility, DMAC or HROW?

Does the media refer more to DMAC or HROW?

Do insiders & institutionals hold more shares of DMAC or HROW?

Is DMAC or HROW more profitable?

Do analysts recommend DMAC or HROW?

Which has higher valuation & earnings, DMAC or HROW?

Summary

How does DiaMedica Therapeutics compare to WAVE Life Sciences?

Which has higher earnings & valuation, DMAC or WVE?

Which has more risk & volatility, DMAC or WVE?

Do analysts rate DMAC or WVE?

Does the media favor DMAC or WVE?

Do insiders and institutionals hold more shares of DMAC or WVE?

Is DMAC or WVE more profitable?

Summary

How does DiaMedica Therapeutics compare to Maplight Therapeutics?

Do insiders & institutionals hold more shares of MPLT or DMAC?

Is MPLT or DMAC more profitable?

Which has higher valuation and earnings, MPLT or DMAC?

Do analysts rate MPLT or DMAC?

Does the media refer more to MPLT or DMAC?

Summary

How does DiaMedica Therapeutics compare to Olema Pharmaceuticals?

Which has more risk and volatility, DMAC or OLMA?

Is DMAC or OLMA more profitable?

Which has better earnings & valuation, DMAC or OLMA?

Do analysts prefer DMAC or OLMA?

Do institutionals & insiders believe in DMAC or OLMA?

Does the media favor DMAC or OLMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC vs. The Competition

DiaMedica Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools